Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.

Revenue
+19.2%
EPS
+64.1%
Free cash flow
−29.8%
Total debt
−5.19%

Quarter to September 2026, against a year earlier

146.38 9.74 −6.24%
Market cap
$10.8B
P/E
23.8×
Fwd P/E
24.4×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a

Insulet Corporation 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:05 PM ET · Document on sec.gov · Filing index

Red flags

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 5, 2026: no material changes, the filing says